.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of people along with HER2+ sophisticated bosom cancer and active or even dependable brain metastases revealed consistent intracranial task as well as systemic efficiency of T-DXd.